As of December 31, 2023, Cingulate had $52,416 in cash and cash equivalents. “I am pleased to report that Cingulate is stronger today than the end of last year,” said Shane J. Schaffer, Chairman and CEO of Cingulate Inc. “With the addition of three independent directors, each of whom possess deep experience in the pharmaceutical industry, small-cap publicly traded companies, and hold executive leadership roles within pharma, the Cingulate board is equipped to overcome the challenges ahead.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
- Cingulate to Participate in Benzinga All Live Access Event
- Cingulate to Attend DCAT Week 2024 in New York City
- CING Upcoming Earnings Report: What to Expect?
- Cingulate Inc Bolsters Board, Targets Nasdaq Compliance
